Why the study?
OAC-induced diffuse alveolar hemorrhaging forces OAC discontinuation and high-dose corticosteroid use, creating a clinical dilemma that increases the risk of stroke and cardiovascular events.
Answers are grounded in this paper and cite their sources.
Percutaneous LAA closure may be a viable strategy to manage patients with atrial fibrillation who develop life-threatening OAC-induced diffuse alveolar hemorrhaging, allowing for safe OAC discontinuation.
Diffuse alveolar hemorrhaging (DAH) due to oral anticoagulation (OAC) is a life-threatening condition that leads to severe respiratory failure. There is a clinical dilemma in that OAC-induced DAH often forces the discontinuation of OAC therapy and the administration of high-dose corticosteroids, which increases the risk of stroke and cardiovascular events. We herein report the first case of OAC-induced DAH and atrial fibrillation (AF) in a patient who completely discontinued OAC therapy and high-dose corticosteroids after experiencing percutaneous left atrial appendage (LAA) occlusion. This case suggests that percutaneous LAA closure may aid in the management of OAC-induced DAH and AF.
No takes yet. Share an insight, caveat, or question.
Ogoshi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: